DiaMedica Therapeutics (DMAC) Resumen de Acciones
DiaMedica Therapeutics Inc, empresa biofarmacéutica en fase clínica, se centra en mejorar la vida de las personas que padecen enfermedades isquémicas graves. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 0/6 |
| Crecimiento futuro | 0/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 6/6 |
| Dividendos | 0/6 |
DMAC Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de DiaMedica Therapeutics Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$6.06 |
| Máximo en las últimas 52 semanas | US$10.42 |
| Mínimo de 52 semanas | US$3.48 |
| Beta | 0.99 |
| Cambio en 1 mes | -11.53% |
| Variación en 3 meses | -30.34% |
| Cambio de 1 año | 41.92% |
| Variación en 3 años | 116.43% |
| Variación en 5 años | -11.01% |
| Variación desde la OPV | -81.87% |
Noticias y actualizaciones recientes
Companies Like DiaMedica Therapeutics (NASDAQ:DMAC) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Preeclampsia Breakthrough Potential And Strong Cash Runway Will Support Future Value Creation
Catalysts About DiaMedica Therapeutics DiaMedica Therapeutics is a clinical stage biopharmaceutical company focused on developing DM199, a KLK1 protein therapy, for vascular conditions such as preeclampsia, fetal growth restriction and acute ischemic stroke. What are the underlying business or industry changes driving this perspective?Recent updates
Companies Like DiaMedica Therapeutics (NASDAQ:DMAC) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Preeclampsia Breakthrough Potential And Strong Cash Runway Will Support Future Value Creation
Catalysts About DiaMedica Therapeutics DiaMedica Therapeutics is a clinical stage biopharmaceutical company focused on developing DM199, a KLK1 protein therapy, for vascular conditions such as preeclampsia, fetal growth restriction and acute ischemic stroke. What are the underlying business or industry changes driving this perspective?
Preeclampsia And Stroke Programs Will Drive Long Term Potential For This Biotech
Catalysts About DiaMedica Therapeutics DiaMedica Therapeutics is a clinical stage biopharmaceutical company focused on developing DM199, a recombinant KLK1 therapy, for vascular conditions such as preeclampsia, fetal growth restriction and acute ischemic stroke. What are the underlying business or industry changes driving this perspective?Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...We Think DiaMedica Therapeutics (NASDAQ:DMAC) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...FDA puts DiaMedica's phase 2/3 trial for its stroke treatment DM199 on clinical hold
DiaMedica Therapeutics (NASDAQ:DMAC) on Wednesday said the U.S. FDA had placed a clinical hold on its phase 2/3 trial evaluating its product candidate DM199 for the treatment of a type of stroke called acute ischemic stroke. The trial, called ReMEDy2, was put on hold as three serious cases of low blood pressure in stroke patients were reported after they received an injection of DM199. The company said it had paused patient enrollment, and believes the low blood pressure events were due to the use of a different intravenous bag in the ReMEDy2 trial from the one used in the prior ReMEDy1 trial. "...the company is confirming the differences in drug absorption in the IV bags used in the ReMEDy1 trial compared to the ReMEDy2 trial and plans to work with the FDA to modify the ReMEDy2 trial protocol to adjust the DM199 IV dosing to more closely match the dosing in the ReMEDy1 trial, taking into account these differences", DMAC said. DMAC said that no such low blood pressure issues were reported in the ReMEDy1 trial.We're Not Very Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...DiaMedica: Proven Stroke Drug In Asia, Headed To The U.S.
DMAC is a microcap biotech that has the first potential breakthrough stroke drug in 25 years, which addresses a $3.5 billion U.S. market. They initiated a phase 2/3 pivotal trial. Their drug, DM199, is the first synthetic version of a naturally occurring protein, KLK1. Porcine and human-derived KLK1 have been used for 20+ years in Asia to treat stroke/kidney disease. A near-term Asian strategic partner could provide a $5-$20 million upfront payment with a potential of $50+ million in milestone payments for DM199 distribution rights. Insider buying of 110K+ shares in Q3-2021 is a very positive signal. The average price target from 5 Wall Street analysts is $22, or 5x the current price. A recent capital raise eliminates concern over any future dilution. No capital should be needed until mid-2023 after the pivotal stroke study results are released and the kidney indications.Rentabilidad de los accionistas
| DMAC | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | -6.0% | -1.8% | -0.3% |
| 1Y | 41.9% | 32.7% | 24.1% |
Rentabilidad vs. Industria: DMAC superó a la industria US Biotechs, que obtuvo un rendimiento del 32.7% el año pasado.
Rentabilidad vs. Mercado: DMAC superó al mercado US, que obtuvo un rendimiento del 24.1% el año pasado.
Volatilidad de los precios
| DMAC volatility | |
|---|---|
| DMAC Average Weekly Movement | 6.3% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Precio estable de las acciones: DMAC no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de DMAC (6%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2000 | 35 | Rick Pauls | www.diamedica.com |
DiaMedica Therapeutics Inc, empresa biofarmacéutica en fase clínica, se centra en mejorar la vida de las personas que padecen enfermedades isquémicas graves. Su principal candidato es DM199, una forma recombinante farmacéuticamente activa de la proteína humana calicreína tisular-1, que se encuentra en ensayos de fase 2/3 para el tratamiento del ictus isquémico agudo, así como en fase 2 para tratar la preeclampsia, la enfermedad cardio-renal y la restricción del crecimiento fetal. La empresa desarrolla DM300, que es una ulinastatina humana recombinante en fase preclínica para el tratamiento de enfermedades inflamatorias, como la pancreatitis aguda.
Resumen de fundamentos de DiaMedica Therapeutics Inc.
| Estadísticas fundamentales de DMAC | |
|---|---|
| Capitalización bursátil | US$326.53m |
| Beneficios(TTM) | -US$35.10m |
| Ingresos (TTM) | n/a |
¿Está DMAC sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de DMAC | |
|---|---|
| Ingresos | US$0 |
| Coste de los ingresos | US$0 |
| Beneficio bruto | US$0 |
| Otros gastos | US$35.10m |
| Beneficios | -US$35.10m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.65 |
| Margen bruto | 0.00% |
| Margen de beneficio neto | 0.00% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado DMAC a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/18 20:07 |
| Precio de las acciones al final del día | 2026/05/15 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
DiaMedica Therapeutics Inc. está cubierta por 13 analistas. 5 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Joshua Schimmer | Cantor Fitzgerald & Co. |
| Kyle Bauser | Colliers Securities |
| Chase Knickerbocker | Craig-Hallum Capital Group LLC |